The place of pasireotide in precision treatment of patients with acromegaly DOI Creative Commons
E.V. Pronin, T. M. Alexeeva, Vyacheslav Pronin

и другие.

Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 16, С. 193 - 205

Опубликована: Ноя. 1, 2024

Due to the syndromal nature of acromegaly, effectiveness its treatment depends on consideration age, clinical and pathomorphological features disease, which determine logistics selection personalized therapeutic measures. The disadvantage used empirical pharmacotherapy scheme with help ‘trial error’ method is formal prescription drugs without taking into account peculiarities morphofunctional status supervised GH-secreting tumors targeting drugs. lack differentiated approach acromegaly accompanied by a high percentage failures, also deliberately deprives significant proportion patients opportunity achieve timely safe control disease improve quality life. review presents comparative analysis modern in focus efficacy second-generation somatostatin receptor ligand – pasireotide. mechanism action pharmacotherapeutic possibilities pasireotide LAR are considered. niche for this drug presence sparsely granulated somatotrophic tumor (SGST), characterized aggressive course, tendency recurrence refractoriness therapy first-generation ligands.Implementation precision using clinical, morphological, radiological functional predictors allows not only identify specific morphotype tumor, but predict planned treatment. A table multidirectional biomarkers long-term sensitivity cells first- ligands presented. When SGST, large size residual poor expression 2nd subtype receptors detected, can be as 1st-line treatment, both mono- combination pegvisomant. Special caution required when treating diabetes mellitus or predisposition development. paper discusses detail measures aimed at prevention, dynamic correction pasireotide-associated hyperglycemia.

Язык: Английский

The place of pasireotide in precision treatment of patients with acromegaly DOI Creative Commons
E.V. Pronin, T. M. Alexeeva, Vyacheslav Pronin

и другие.

Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 16, С. 193 - 205

Опубликована: Ноя. 1, 2024

Due to the syndromal nature of acromegaly, effectiveness its treatment depends on consideration age, clinical and pathomorphological features disease, which determine logistics selection personalized therapeutic measures. The disadvantage used empirical pharmacotherapy scheme with help ‘trial error’ method is formal prescription drugs without taking into account peculiarities morphofunctional status supervised GH-secreting tumors targeting drugs. lack differentiated approach acromegaly accompanied by a high percentage failures, also deliberately deprives significant proportion patients opportunity achieve timely safe control disease improve quality life. review presents comparative analysis modern in focus efficacy second-generation somatostatin receptor ligand – pasireotide. mechanism action pharmacotherapeutic possibilities pasireotide LAR are considered. niche for this drug presence sparsely granulated somatotrophic tumor (SGST), characterized aggressive course, tendency recurrence refractoriness therapy first-generation ligands.Implementation precision using clinical, morphological, radiological functional predictors allows not only identify specific morphotype tumor, but predict planned treatment. A table multidirectional biomarkers long-term sensitivity cells first- ligands presented. When SGST, large size residual poor expression 2nd subtype receptors detected, can be as 1st-line treatment, both mono- combination pegvisomant. Special caution required when treating diabetes mellitus or predisposition development. paper discusses detail measures aimed at prevention, dynamic correction pasireotide-associated hyperglycemia.

Язык: Английский

Процитировано

0